Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LNS8801 in Patients With Advanced Cancer With and Without Pembrolizumab
NCT04130516Phase 2Active, not recruiting
- Sponsor
- Linnaeus Therapeutics
- Start
- Oct 2019
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lns-8801 in solid tumor, sponsored by Linnaeus Therapeutics. Started Oct 2019; status: active, not recruiting.
02
Drugs
lns-8801
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04130516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04130516.